Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients

Xiaoqin Lai1 | Wenfa Chen1 | Yuzhu Wu1 | Yali Gao1 | Yalan Zhang1 | Xuwei Xu1 | Ya Fu2 | Xinwen Wang3 | Yanbing Yang4 | Yin Zhang1

1Pharmacy Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China
2Department of Clinical Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
3Department of Orthopedics, Southern Medical University, Guangzhou, China
4Department of Imaging, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China

Correspondence
Yin Zhang, Pharmacy Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China. Email: fmuzyin@163.com
Yanbing Yang, Department of Imaging, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China. Email: fmuyyb@163.com

Funding information
The study was supported by grants from Educational Research for Middle-age and Young Teachers (Technological Division), Department of Education of Fujian Province (JAT200135)

Abstract
It was known that mutations in the RT region were mainly related to nucleot(s)ide analogs resistance. Increasing studies indicated that RT mutations were related to advanced liver diseases (ALD) and had effects on HBV replication, but the distribution characteristics of mutations across RT region in the development of liver diseases and the effect of RT mutations on HBV replication were not fully clarified. HBV RT region was direct-sequenced in 1473 chronic HBV-infected patients. Mutation frequencies were analyzed to identify the specific mutations differing between groups classified by genotypes, loads of HBV DNA, or progression of liver diseases. In the range of rt145-rt290, rt145, rt221, rt222, rt267, and rt271 were the genotype-polymorphic sites, while rt238 was the genotype-specific sites. Mutations at rt163, rt173, rt180, rt181, rt184, rt191, rt199, and rt214 were more frequent among patients with C-genotype HBV, while those at rt220, rt225, rt226, rt269, and rt274 were more frequent among patients with B-genotype HBV. RtM204V/I could reduce the HBV DNA loads while rtQ/L267H/R could increase the HBV DNA loads. RtV214A/E/I (OR 3.94, 95% CI 1.09 to 14.26) was an independent risk factor for advanced liver diseases. In summary, the hotspots of mutations were different between B and C genotypes. Besides the effect on the S region, RT mutations had effects on HBV replication by other unknown ways. RtV214A/E/I was found to be an independent risk factor for ALD, suggesting that mutations at rt214 site could be used as a potential virological marker for the liver disease progression.

KEYWORDS
HBV, liver disease progression, mutation, replication, RT region

1 | INTRODUCTION

Hepatitis B virus (HBV) is a DNA virus, belonging to the family of Hepadnaviridae DNA viruses, which is the pathogen that causes hepatitis B.1 At present, there are about 257 million people infected chronically with HBV in the world, accounting for about 3.5% of the global population.1 Uncontrolled chronic HBV infection can develop into life-threatening advanced liver diseases, including liver cirrhosis (LC) and hepatocellular carcinoma (HCC), posing great challenges to global public health.

The genome of HBV consists of 3.2 kb incomplete double-stranded relaxed circular DNA (rcDNA) and contains 4 open reading frames (ORF), namely P, PreC/C, PreS/S, and X.2 The above four genes are responsible for encoding polymerase protein, HBeAg,
LHBsAg, MHBsAg, SHBsAg, and X protein. Among them, P protein is involved in the process of reverse transcription of HBV pre-genomic RNA into negative-strand DNA.\(^2\)

Since HBV replication lacks a mismatch correction mechanism, the new genome generated by replication is prone to mutations.\(^3\) Among them, mutations in the PreC/C region and X region have been reported to be related to the occurrence of hepatocellular carcinoma.\(^4,5\) Mutations in the PreS/S region are related to immune escape.\(^6\) Besides, mutations in the P region (RT region) have been reported to be mainly related to nucleos(t)ide analogs (NAs) resistance.\(^7\)

Although mutations in the RT region are responsible for NAs resistance, studies have reported that the mutation frequency of rtM204V/I, which was the classic NAs resistance mutation, was significantly higher in patients with advanced liver diseases, such as LC and HCC.\(^8\) Therefore, RT mutations may also be related to the occurrence of HCC, but the distribution characteristics of RT mutations in the occurrence and development of liver disease are still unclear. In addition, classic resistance mutations, such as rtM204V/I, have been reported to reduce the replication of HBV, while the compensation mutation rtL180M could restore the impaired replication capacity caused by rtM204V mutation.\(^9\) Nevertheless, the effect of other RT mutations on HBV replication is still unknown.

In this study, Sanger sequencing was used to detect the HBV RT region sequences from patients with chronic HBV infection. Through analyzing the RT mutations at different HBV replication levels and comparing the characteristics of RT mutations in different liver disease progression, this study aimed to understand the effect of HBV RT mutations on HBV replication and liver disease progression.

### 2 | MATERIALS AND METHODS

#### 2.1 | Patients and blood samples

A total of 1473 chronic HBV-infected patients were enrolled at the First Affiliated Hospital of Fujian Medical University from January 2011 to December 2016 and informed consent on entry into the trials was obtained from all patients. The inclusion criteria were the presence of hepatitis B surface antigen (HBsAg) and HBV DNA at least 6 months prior to treatment. Patients co-infected with the hepatitis A/C/D virus, human immunodeficiency virus, autoimmune liver disease, primary biliary cirrhosis, and alcohol or drug abuse were excluded. All the serum samples were collected and stored at \(-80^\circ\text{C}\). The study was approved by the Ethics Committee of the Second Affiliated Hospital of Fujian Medical University.

#### 2.2 | Laboratory tests

Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were determined by automated biochemical technique (Siemens Healthcare Diagnostics). Serum HBsAg, anti-HBs, hepatitis B e antigen (HBeAg), anti-HBe, and anti-HBc were measured on the wholly automatic immune fluorescence analyzer Abbott Type i4000 (Abbott Laboratories). Serum HBV DNA was quantified using the original, corollary commercial kits. Serum HBV DNA was extracted from 500µl patient serum according to the manufacturer’s instructions of the TIANamp Genomic DNA Kit (Tiangen Biotech). The HBV RT gene was amplified by PCR using forward primer 5'-CTCATGGTGCTGTAACAAACC-3' (nt559-nt579) and reverse primer 5'-CAATTCTGGACATCTTTCCA-3' (nt1000-nt979). PCR was performed in a 50µl mixture containing 2.5mM MgCl\(_2\), 400µM dNTP and 2.5 U of Taq polymerase (TAKARA, Japan). PCR conditions were as follows: 94°C for 5 min; 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min; then 72°C for 10 min. The PCR products were purified using a QIAquick Gel Extraction Kit (Qiagen) and directly sequenced (The Beijing Genomics Institute).

#### 2.3 | HBV DNA extraction and Sanger sequencing

HBV DNA was extracted from 500µl patient serum according to the manufacturer’s instructions of the TIANamp Genomic DNA Kit (Tiangen Biotech). The HBV RT gene was amplified by PCR using forward primer 5'-CTCATGGTGCTGTAACAAACC-3' (nt559-nt579) and reverse primer 5'-CAATTCTGGACATCTTTCCA-3' (nt1000-nt979). PCR was performed in a 50µl mixture containing 2.5mM MgCl\(_2\), 400µM dNTP and 2.5 U of Taq polymerase (TAKARA, Japan). PCR conditions were as follows: 94°C for 5 min; 35 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 1 min; then 72°C for 10 min. The PCR products were purified using a QIAquick Gel Extraction Kit (Qiagen) and directly sequenced (The Beijing Genomics Institute).

#### 2.4 | Sequence alignment and HBV genotyping

Mutations were analyzed by aligning HBV RT sequences with the consensus sequence generated based on the HBV RT sequences in this study and the reference sequences in previous studies according to published literature.\(^10\) In brief, 100 B-genotype DNA sequences (Supplementary material 1) and 100 C-genotype DNA sequences (Supplementary material 2) were aligned to obtain the consensus sequence generated based on the HBV RT sequences above to analyze the mutation. We used the phylogenetic analysis for HBV genotyping (Figure S1). Meanwhile, an online tool Genotyping (https://www.ncbi.nlm.nih.gov/projects/genotyping/formpage.cgi) was also applied to verify the accuracy of HBV genotyping.

#### 2.5 | Statistical analysis

Differences in measurement data were evaluated by t test, Mann-Whitney U test, Kruskal-Wallis test, chi-square test (Fisher’s exact test was used when needed), and two-logistic regression with IBM SPSS Statistics software (Version 22.0.0; IBM). All p-values were two-tailed. \(p < 0.05\) was considered statistically significant.

### 3 | RESULTS

#### 3.1 | Clinical characteristics of patients

A total of 1445 subjects with chronic HBV infection who underwent Sanger sequencing were included in this study. The sequencing range of the RT region covers rt145-rt290. This study first
LAI et al. compared the clinical characteristics of patients with chronic HBV infection between B and C genotype and found that the distribution of patients with B- or C-genotype HBV at different age groups, HBeAg status, and disease progression showed significant differences (Table 1). Next, this study grouped chronic HBV carriers (CC) and chronic hepatitis B (CHB) patients into one group, and grouped liver cirrhosis (LC) and hepatocellular carcinoma (HCC) patients into another group. The clinical characteristics of the above two groups were compared. Gender, genotype, age, ALT, HBV DNA, HBsAg, HBeAg, and AFP, except HBCab, were significantly different between (CC + CHB) and (LC + HCC) groups (Table 2).

### 3.2 Effect of genotype on RT mutations

Before the analysis of RT mutations, this study first determined the reference sequences of B- and C-genotype HBV. In this study, 100 cases of B-genotype HBV DNA sequences and 100 cases of C-genotype HBV DNA sequences were first aligned respectively to obtain the consensus sequences of the B- and C-genotype HBV. These two consensus sequences were taken as reference sequences for this study.

By using VESPA (https://www.hiv.lanl.gov/content/sequence/VESPA/vespa.html), we found that in the range of rt145-rt290,

| TABLE 1 | Clinical data of the subjects in this study were compared according to the different genotypes |
|---------|---------------------------------------------------------------------------------|
| Gender  |                                                                                  |
|         | Genotype-B (%)                      | Genotype-C (%)                      | $\chi^2$ | $p$    |
| Female  | 194 (25.1)                          | 200 (28.6)                          | 2.4      | 0.13   |
| Male    | 580 (74.9)                          | 499 (71.4)                          |          |        |
| Age (years) |                                                                |                                      |          |        |
| <30     | 305 (39.4)                          | 173 (24.8)                          | 48.8     | <0.001 |
| 30–39   | 232 (30.0)                          | 200 (28.7)                          |          |        |
| ≥40     | 237 (30.6)                          | 325 (46.5)                          |          |        |
| Serum ALT level (U/L) |                                    |                                      |          |        |
| <40 (female) or 50 (male) | 116 (20.8)                      | 108 (22.7)                          | 2.0      | 0.38   |
| 40–79 (female) or 50–99 (male) | 96 (17.2)                          | 93 (19.5)                           |          |        |
| ≥80 (female) or ≥100 (male) | 346 (62.0)                          | 275 (57.8)                          |          |        |
| Serum HBV DNA level (IU/ml) |                                    |                                      |          |        |
| <200,000 | 190 (33.0)                          | 174 (34.3)                          | 0.20     | 0.66   |
| ≥200,000 | 385 (67.0)                          | 333 (65.7)                          |          |        |
| Serum HBsAg level (IU/ml) |                                    |                                      |          |        |
| <100    | 14 (2.5)                            | 16 (3.2)                            | 1.06     | 0.59   |
| 100–999 | 58 (10.5)                           | 60 (12.0)                           |          |        |
| ≥1000   | 482 (87.0)                          | 426 (84.8)                          |          |        |
| Serum HBeAg status |                                |                                      |          |        |
| Positive| 375 (66.1)                          | 377 (78.4)                          | 19.24    | <0.001 |
| Negative| 192 (33.9)                          | 104 (21.6)                          |          |        |
| Serum AFP status (ng/ml) |                                    |                                      |          |        |
| <25     | 330 (76.9)                          | 285 (78.7)                          | 2.24     | 0.33   |
| 25–399  | 85 (19.8)                           | 60 (16.6)                           |          |        |
| ≥400    | 14 (3.3)                            | 17 (4.7)                            |          |        |
| Disease process |                                |                                      |          |        |
| Chronic carrier | 240 (31.0)                            | 223 (32.0)                          | 40.18    | <0.001 |
| Chronic hepatitis | 412 (53.3)                        | 298 (42.8)                          |          |        |
| Liver failure | 19 (2.5)                                | 5 (0.7)                             |          |        |
| Liver cirrhosis | 82 (10.6)                        | 136 (19.5)                          |          |        |
| Hepatocellular carcinoma | 20 (2.6)                                | 34 (5.0)                            |          |        |

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase.

*aPartial data missing.*
rt145, rt151, rt221, rt222, rt223, rt224, rt238, rt267, and rt271 are genotype-dependent sites (Figure 1A and Figure S3). After clarifying the genotype-dependent sites, we analyzed the amino acid changes between B and C genotypes at these above sites. The results showed that rt221, rt222, rt267, and rt271 had significantly more amino acid changes between B and C genotypes (Figure 1B), suggesting that these sites are genotype-polymorphic sites. Moreover, in our study, there were no amino acid changes at rt238 and rt263 between B and C genotypes, suggesting that these sites are relatively conservative, that is, genotype-specific sites (Figure 1B).

After analyzing the amino acid changes between B and C genotypes at genotype-dependent sites, this study also investigated the differences of mutations from rt145 to rt290 between B and C genotypes. We first observed the distribution of mutations across RT region of B- and C- genotype HBV, respectively (Figure 1H). The results showed that in the range of rt145-rt217, it seemed that there were more mutations across RT region of C- genotype HBV (Figure 1H). While in the range of rt218-rt290, there seemed to be more mutations across RT region of B-genotype HBV (Figure 1H). After further statistical analysis, it was found that mutations at rt145, rt163, rt173, rt180, rt181, rt184, rt191, rt199, and rt214 were significantly more in C-genotype HBV (Figure 1I). The mutations at rt220, rt225, rt226, rt269, and rt274 are significantly more in B-genotype HBV (Figure 1I).

### 3.3 Effect of RT mutations on HBV replication

Some studies have shown that the classic drug-resistant mutation rtM204V/I could reduce the replication capacity of HBV, but the effect of other RT mutations on HBV replication is still not completely clear. Therefore, this study analyzed the effect of mutations at rt145-rt290 on HBV replication.

The average HBV DNA level of subjects in this study was 6.08 (log_{10}, IU/ml). Based on this average level, the study divided the subjects into two groups, that is, ≥6.08 (log_{10}, IU/ml) group and <6.08 (log_{10}, IU/ml) group. This study first investigated the distribution of RT mutations in the above two groups. Intuitively from

| TABLE 2 Clinical data of the subjects in this study were compared according to the progression of liver diseases |
|---|---|---|---|
| **Gender** | CC + CHB (n = 1173) | LC + HCC (n = 272) | χ²/t/Z | p |
| Female (%) | 330 (28.1) | 56 (20.6) | 6.420 | 0.011 |
| Male (%) | 843 (71.9) | 216 (79.4) | | |
| **Genotype** | | | | |
| B (%) | 652 (55.6) | 102 (37.5) | 28.938 | <0.001 |
| C (%) | 521 (44.4) | 170 (62.5) | | |
| **Age (years), (mean ± 2SD)** | | | | |
| 34.2 ± 11.1 | 49.2 ± 11.5 | -19.916 | <0.001 |
| **Serum ALT level (ULN), (mean ± 2SD)** | | | | |
| 5.9 ± 7.1 | 2.9 ± 4.6 | 7.217 | <0.001 |
| **Serum HBV DNA level (log_{10}, IU/ml), (mean ± 2SD)** | | | | |
| 6.2 ± 1.5 | 5.5 ± 1.4 | 6.315 | <0.001 |
| **Serum HBsAg level (IU/mL), (mean ± 2SD)** | | | | |
| 19188.1 ± 27719.6 | 9970.5 ± 22424.0 | 5.033 | <0.001 |
| **Serum HBeAg status** | | | | |
| Positive (%) | 626 (75.1) | 116 (58.6) | 21.494 | <0.001 |
| Negative (%) | 208 (24.9) | 82 (41.4) | | |
| **Serum HBcAb level (S/CO), (mean ± 2SD)** | | | | |
| 12.1 ± 3.2 | 11.9 ± 2.6 | 0.721 | 0.471 |
| **Serum AFP status (ng/ml), (median, range)** | | | | |
| 4.56 (0.71–44.756) | 7.31 (1–60,500) | -3.645 | <0.001 |

Abbreviations: CC, chronic carrier; CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; LC, liver cirrhosis.

*Partial data missing.*
the distribution map, RT mutations from subjects between the two groups may differ only in individual sites (Figure 2A). After further statistical analysis, mutations at rt180, rt204, and rt250 were significantly more in the <6.08 (log10, IU/ml) group, while mutations at rt267 were significantly more in the ≥6.08 (log10, IU/ml) group (Figure 2B).

Because rtL180M is a compensatory mutation of rtM204V, it exists in linkage with rtM204V. RtM250L/V, as one of the resistance mutations of entecavir (ETV), is often generated on the basis of the occurrence of rtM204V+rtL180M. However, the correlation between rtQ/L267H/R and rtM204V/L is unknown. Therefore, in this study, the associations of rtM204V/I with rtL180M, rtM250L/V, or rtQ/L267H/R were analyzed respectively by McNemar's test. The results showed that rtL180M and rtM250L/V were significantly correlated with rtM204V/I, while rtQ/L267H/R was significantly uncorrelated with rtM204V/I (Table 3).

Whereafter, we compared the HBV DNA loads of subjects with and without rtM204V/I. The effects of rtL180M and rtM250L/V on the replication of HBV with rtM204V/I were also analyzed respectively. The results showed that the HBV DNA load of subjects with rtM204V/I was significantly lower than that of subjects without rtM204V/I (Figure 2C). Although there was no statistically significance found, rtL180M seemed to slightly increase the HBV DNA load of subjects with rtM204V/I (Figure 2D), while rtM250L/V could slightly reduce the HBV DNA load of subjects with rtM204V/I (Figure 2E). Interestingly, the HBV DNA load of subjects with rtQ/L267H/R was significantly higher than that of subjects without rtQ/L267H/R (Figure 2F).

Some studies reported that the effect of RT mutations on HBV replication might be because that RT mutations could lead to the change of amino acid on S region. Therefore, this study also analyzed the effects of rtL180M, rtM204V/I, rtM250L/V, and rtQ/L267H/R on S region. We found that rtM204V caused s195M and rtM204I caused sW196L within S region. However, rtL180M, rtM250L/V, and rtQ/L267H/R did not lead to the changes of S region (Figure 2G). Therefore, the effect of RT mutations on HBV replication was not only caused by changes in S region.

### 3.4 Correlations between RT mutations and liver disease progression

Mutations in the RT region are mainly related to NAs resistance. Some studies have shown that rtM204V was related to the occurrence of HCC. However, the correlation between other RT mutations and the progression of liver diseases is still unknown. Therefore, this study explored the correlation between RT mutations and liver disease progression within the range of rt145-rt290. In this study, chronic HBV carriers (CC) and patients with chronic hepatitis B (CHB) were grouped into one group, and patients with liver cirrhosis (LC) and those with hepatocellular carcinoma (HCC) were grouped into another group, namely (CC + CHB) group and (LC + HCC) group.

The distribution of mutations across RT region from subjects in the above two groups was analyzed firstly. Intuitively from the distribution map, the subjects from (LC + HCC) group seemed to have more RT mutations (Figure 3A). Further statistical analysis found that there were significantly more mutations at multiple sites in (LC + HCC) group, including rtL180M, rtA181V/T/S/G, rtT184A/I, rtL199V, rtV207F/I/L/M, rtS213I, rtV214A/E/I, rtS219A, and rtL220I (Figure 3B).

Since some studies have shown that gender, age, HBV genotype, and HBeAg status were related to the advanced liver diseases (such as LC and HCC), the logistic regression analysis was used to investigate significantly different RT mutations between (CC and CHB) group and (LC + HCC) group, and adjusted for gender, age, HBV genotype, and HBeAg status. The results showed that the appearance of rtV214A/E/I (OR 3.94, 95% CI 1.09 to 14.26) was an independent risk factor for advanced liver diseases (Figure 3C).

### 4 DISCUSSION

Several studies have targeted genotype-dependent sites based on PCR for HBV genotyping, such as the COLD-PCR/FMCA method using specific probes for genotype-specific base sites for genotyping.\textsuperscript{11} In this study, we identified 9 genotype-dependent aa sites (Figure 1B). Among these sites, rt145, rt221, rt222, rt267, and rt271 had significant amino acid changes between B and C genotypes (Figure 1B-G), indicating that these sites were genotype-polymorphic sites. In contrast, there were no amino acid changes found at rt238 between genotypes B and C (Figure 1B), indicating that this site was a genotype-specific site. Therefore, the identification for types of amino acids at rt238 site could be used to distinguish genotypes B and C.

Some investigators have reported that NAs-resistant mutations had the bias to different genotypes. Li et al.\textsuperscript{12} found that genotype-C HBV had significantly more rtM204V/I, rtA181V, rtM204V/I plus rtT184substitution or rtS202G, while genotype-B HBV harbored significantly more rtN236T and rtM204V/I plus rtM250V/I/L. In this study, our results were generally similar to those of Li et al., but we did not find the difference in the mutation frequency of rtM204V/I and rtN236T between genotypes B and C (Figure 1I). In addition, this study, it was found that the classic compensatory mutations

---

**Figure 2** RT mutations had effects on the HBV replication. (A) The distributions of mutations across RT region were observed in patients with loads of HBV DNA <6.08 or ≥6.08 (log10, IU/ml), respectively. (B) The mutation frequencies were significantly different at rt180, rt204, rt250, and rt267 between patients with loads of HBV DNA <6.08 and those with loads of HBV DNA ≥6.08 (log10, IU/ml). (C-F) The loads of HBV DNA were compared between patients with and without the corresponding mutations. (G) The effects of rtL180M, rtM204V/I, rtM250L/V, and rtQ/L267H/R on S region were analyzed.
rtV173L and rtL180M were significantly more in patients infected with genotype-C HBV (Figure 1). In short, combined with the existing studies and this study, the risk of entecavir resistance in patients infected with genotype-C HBV was higher than that of patients infected with genotype-B HBV. Notably, this study found that in the range of rt145-rt214, patients infected with genotype-C HBV had significantly more RT mutations (Figure 1H,I), further suggesting that the distribution of patients infected with genotype-B HBV had significantly more RT mutations (Figure 1H,I), further suggesting that the distribution of mutations across RT region were different between genotypes B and C.

Several studies have reported that mutations within the RT region could affect the replication of HBV.13–17 rtM204V/I, rtL228W, and rtL229W could reduce the capacity of HBV to replicate, while rtL180M could partially reduce the effect of rtM204V on replication.17,18 Besides, mutations in the pre-C region (PC) and basal core promoter (BCP) could increase the replication of HBV, but rtA194T could reduce the replication of HBV.15 In this study, among the subjects with chronic HBV infection, rtM204V was also found to reduce the replication of HBV, but we did not find that rtA194T, rtL228W, and rtL229W had a significant impact on the replication of HBV (Figure 2A-C). These results suggest that mutations within the RT region did not have the same effect on the replication of HBV in vivo and in vitro, which might be caused by a more complex environment in vivo. Notably, through comparing RT mutations between 6.08 (log_{10} IU/ml) group and 〈6.08 (log_{10} IU/ml) group, we have found that rtQ/L267H/R was likely to enhance the capacity of HBV to replicate (Figure 2B). Given the unknown impact of rtQ/L267H/R on the replication of HBV, viral loads of subjects with rtQ/L267H/R were analyzed further to prove in vivo that rtQ/L267H/R could increase the replication of HBV (Figure 2F). In order to determine the role of rtQ/L267H/R, cell and animal experiments needed to be performed to prove the effect of rtQ/L267H/R on the replication of HBV in the future.

TABLE 3 Relations between rt204 and rt180, rt204 and rt250, or rt204 and rt267 were analyzed respectively by McNemar’s test

|                      | With rtM204V/I | Without rtM204V/I | p       |
|----------------------|---------------|------------------|---------|
| with rtL180M         | 76            | 1                | <0.001  |
| without rtL180M      | 87            | 919              |         |
| with rtM250V/I/L     | 12            | 1                | <0.001  |
| without rtM250V/I/L  | 151           | 919              |         |
| with rtQ/L267H/R     | 1             | 10               | <0.001  |
| without rtQ/L267H/R  | 162           | 910              |         |

It was reported that the effect of RT mutation on HBV replication might be due to the fact that mutations within the RT region could affect its overlapping S region.14–16,19,20 For example, rtA181T could cause sW172stop.15,16 In order to explore the factors affecting replication of HBV by rtM204V/I and rtQ/L267H/R, we analyzed the effects of rtM204V/I and rtQ/L267H/R on the S region. The results showed that rtM204V and rtM204I could cause sL195M and sW196L, respectively (Figure 2G), which was consistent with the previous studies.20,21 However, rt267 was not located in the overlapping region of RT and S, so rtQ/L267H/R did not affect the protein encoded by preS/S (Figure 2G). Therefore, besides the effect on the S region, mutations located in RT region might also cause changes in the replication of HBV through other unknown ways.

Although HBV X gene was thought to be responsible for the progression of liver diseases,22,23 increasing studies revealed that RT mutations were also related to the advanced liver diseases.24–27 For example, rtM204V/I was found to be more frequent among HCC patients than that among CHB patients.28 Although rtF221Y was identified as a polymorphic change between B and C genotypes in this study (Figure 1B), it was thought to be a risk factor for poor prognosis of HCC.29 In addition, rtL80I, rtD134N, rtY141F, rtL228V, etc. were also reported to be related to HCC development.30 In this study, we found that rtL180M, rtA181V/T/S/G, rtT184A/I, rtL199V, rtV207F/I/L/M, rtS213T, rt214A/E/I, rtS219A, and rtL220I occurred more frequently in patients in (LC and HCC) group than those in (CC + CHB) group, but there was no difference in the frequency of rtM204V/I between these two groups (Figure 3B). Since gender, genotype, age, and HBeAg status, which were risk factors for ALD,28–31 were significantly different between the (CC + CHB) and (LC + HCC) groups (Table 2), we used the two-logistic regression to analyze rtL180M, rtA181V/T/S/G, rtT184A/I, rtL199V, rtV207F/I/L/M, rtS213T, rtV214A/E/I, rtS219A, and rtL220I, adjusted by gender, genotype, age, and HBeAg status. The results showed that gender, age, and rtV214A/E/I were independent risk factors for ALD (Figure 3C). The mutations at rt214 site were potential risk factors in the virological breakthrough of NAs-treated patients,32 but its correlation with the disease progression was not reported in the previous studies. Further cell and animal experiments were needed to be carried out to prove the pathogenic mechanism of rtV214A/E/I.

In summary, this study comprehensively compared the mutant characteristics of HBV RT region between different genotypes, different levels of viral loadings and different liver diseases. Our results demonstrated the impacts of genotypes and liver diseases on mutation across RT region and proved that the alteration of amino acid residues at rt214 was an independent risk factor for ALD, providing
(A) Mutation Frequency (%)

Mutation Frequency (%)

CC + CHB

LC + HCC

RT Site

(B) Frequency (%)

CC + CHB

LC + HCC

nL100M

nA181V/T/S/G

nT184A/I

nL180M

nV207I/L/M

nS213T

nS214A/E/I

nS219A

nL220I

Frequency (%)

(C)

Exposure group

OR (95% CI)

Gender

0.61 (0.38, 0.97)

Genotype

1.50 (0.99, 2.27)

Age

1.11 (1.09, 1.13)

HBeAg status

0.99 (0.64, 1.52)

rtL180M

1.89 (0.89, 3.99)

rtA181V/T/S/G

2.17 (0.96, 4.90)

rtT184A/I

0.85 (0.12, 5.89)

rtL199V

3.79 (0.78, 18.42)

rtV207I/L/M

1.35 (0.52, 3.47)

rtS213T

1.39 (0.60, 3.22)

rtV214A/E/I

3.94 (1.09, 14.26)

rtS219A

1.09 (0.29, 4.13)

rtL220I

1.63 (0.54, 4.90)
ACKNOWLEDGMENTS

We would like to thank the study participants for their devotion to the investigation.

CONFLICT OF INTEREST

No potential conflict of interest was reported by the authors.

DATA AVAILABILITY STATEMENT

Requests for data should be directed to the corresponding author

Yin Zhang (fmuzyn@163.com).

REFERENCES

1. Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Not Rev Dis Primers. 2018;4:18035.
2. Tsukuda S, Watashi K. Hepatitis B virus biology and life cycle. Antiviral Res. 2020;208:104925.
3. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1 Suppl):S4-S16.
4. Chaturvedi VK, Singh A, Dubey SK, Hetta HF, John J, Singh MP. Molecular mechanistic insight of hepatitis B virus mediated hepatocellular carcinoma. Microb Pathog. 2019;128:184-194.
5. Kim H, Lee SA, Do SY, Kim BJ. Precore/core region mutations of hepatitis B virus related to clinical severity. World J Gastroenterol. 2016;22(17):4287-4296.
6. Qin Y, Liao P. Hepatitis B virus vaccine breakthrough infection: surveillance of S gene mutants of HBV. Acta Virol. 2018;62(2):115-121.
7. Kim JH, Park YK, Park ES, Kim KH. Molecular diagnosis and treatment of drug-resistant hepatitis B virus. World J Gastroenterol. 2014;20(19):5708-5720.
8. Kim J-E, Lee S-Y, Kim H, Kim K-J, Choe W-H, Kim B-J. Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naive Korean patients infected with genotype C2. World J Gastroenterol. 2017;23(23):4222-4232.
9. Wet D, Yang H, Westland CE, et al. The hepatitis B virus polymerase mutation rtV214A is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003;77(21):11833-11841.
10. Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010;85(3):512-519.
11. Liu C, Lin J, Xun Z, et al. Establishment of coamplification at lower denaturation temperature PCR/fluorescence melting curve analysis for quantitative detection of hepatitis B virus DNA, genotype, and reverse transcriptase mutation and its application in diagnosis of chronic hepatitis B. J Mol Diagn. 2019;21(6):1106-1116.
12. Li X, Liu Y, Xin S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in North China. Microb Drug Resist. 2017;23(4):516-522.
13. Zhu Y, Curtis M, Borroto-Esoda K. The YMDD and rtA194T mutations result in decreased replication capacity in wild-type HBV as well as in HBV with precore and basal core promoter mutations. Antivir Chem Chemother. 2011;22(1):13-22.
14. Wang T, Cui D, Chen S, et al. Analysis of clinical characteristics and S gene sequences in chronic asymptomatic HBV carriers with low-level HBsAg. Clin Res Hepatol Gastroenterol. 2019;43(2):179-189.
15. Zhou LY, Chen EQ, Wang ML, et al. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems. Sci Rep. 2016;6:39260.
16. Ahn SH, Park YK, Park ES, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88(12):6805-6818.
17. Qin B, Zhou Y, Zhou G, Xu X, Wang Y, Chen J. Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs. Mol Med Rep. 2017;16(6):9678-9684.
18. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-398.
19. Kuhnhen L, Jiang B, Kubesch A, et al. Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg-negative chronic HBV infection. Aliment Pharmacol Ther. 2018;47(11):1523-1535.
20. Wang M-L, Tang H. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis. Hepatobiliary Pancreat Dis Int. 2016;15(6):579-586.
21. Fernandez-Galindo DA, Sanchez-Avila F, Bobadilla-Morales L, et al. New amino acid changes in drug resistance sites and HBsAg in hepatitis B virus genotype H. J Med Virol. 2015;87(6):985-992.
22. Lin CL, Kao JH. Natural history of acute and chronic hepatitis B: the role of HBV genotypes and mutants. Best Pract Res Clin Gastroenterol. 2017;31(3):249-255.
23. Zhou Y, Wan Y, Ye ZW, He Z, Liu Q, Shi Y. How hepatitisB virus causes cirrhosis and liver cancer. Med Hypotheses. 2017;108:52-53.
24. Wu Y, Gan Y, Gao F, et al. Novel natural mutations in the hepatitis B virus reverse transcriptase domain associated with hepatocellular carcinoma. PLoS One. 2014;9(5):e94864.
25. Hi L, Jia J, Wang M, et al. F221Y mutation in hepatitis B virus reverse transcriptase is associated with hepatocellular carcinoma prognosis following liver resection. Mol Med Rep. 2017;15(5):3292-3300.
26. Zheng J, Zeng Z, Zhang D, Yu Y, Wang F, Pan CQ. Prevalence and significance of hepatitis B reverse transcriptase mutants in different disease stages of untreated patients. Liver Int. 2012;32(10):1535-1542.
27. Choi YM, Lee SY, Kim BJ. Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression. World J Gastroenterol. 2018;24(16):1708-1724.
28. Li H, Rong Z, Wang H, et al. Proteomic analysis revealed common, unique and systemic signatures in gender-dependent hepatocarcinogenesis. Biol Sex Differ. 2020;11(1):46.
29. Mai RY, Zeng J, Mo YS, et al. Artificial neural network model for liver cirrhosis diagnosis in patients with hepatitis B virus-related hepatocellular carcinoma. Ther Clin Risk Manag. 2020;16:639-649.
30. Wei D, Zeng Y, Xing X, et al. Proteome differences between hepatitis B virus genotype-B and genotype-C induced hepatocellular carcinoma revealed by iTRAQ-based quantitative proteomics. J Proteome Res. 2016;15(2):487-498.
31. Jin H, Pan N, Mou Y, Wang B, Liu P. Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regression. Hepatol Res. 2011;41(6):512-523.
32. Li XG, Liu BM, Xu J, Liu XE, Ding H, Li T. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse
transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84(2):207-216.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lai X, Chen W, Wu Y, et al. Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients. J Clin Lab Anal. 2022;36:e24530. doi: 10.1002/jcla.24530